Literature DB >> 17051583

Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase.

Brendan Bingham1, Ru Shen, Smita Kotnis, C Frederick Lo, Bradley A Ozenberger, Nivedita Ghosh, Jeffrey D Kennedy, J Steven Jacobsen, Jill M Grenier, Peter S DiStefano, Lillian W Chiang, Andrew Wood.   

Abstract

BACKGROUND: NARC 1/PCSK9 encodes a novel serine proteinase known to play a role in cholesterol homeostasis. NARC 1 mRNA expression in cerebellar granule neurons (CGNs) was discovered to be induced following an apoptotic injury. Coregulation of known apoptotic mediators (caspase-3 and death receptor 6) raises the possibility that NARC 1 might be involved in the propagation of apoptotic signaling in neurons.
METHODS: CGNs were transfected with EGFP-fusion constructs of wild-type and mutant NARC 1, and a laser scanning cytometry-based method of scoring cell death in transfectants was applied. Use of the poly-caspase inhibitor BAF allowed assessment of the caspase-dependence of the NARC 1 proapoptotic effect.
RESULTS: Wild-type NARC 1 was found to have substantial proapoptotic effects that were only partially reversible by BAF. Mutation of the active site serine or deletion of the catalytic domain resulted in a reduced level of cell death, consistent with loss of the BAF-sensitive component of cell death. NH(2)-terminal deletion constructs of NARC 1 had effects similar to wild-type, both in the absence and presence of BAF, whereas expression of COOH-terminal deletion mutants produced a rate of cell death similar to wild-type in the absence of BAF treatment, but which lacked the capacity to be reduced by treatment with BAF.
CONCLUSION: The mechanism by which NARC 1-EGFP over-expression induces cell death in cultured CGNs remains unclear. Mutation analysis established a positive correlation between the presence of the Narc 1 active site serine in the transiently expressed protein and induction of the BAF-sensitive component of the cell death phenotype. A caspase-independent component proved sufficiently complex to map discretely within the Narc 1 protein. (c) 2006 International Society for Analytical Cytology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051583     DOI: 10.1002/cyto.a.20346

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  19 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

2.  PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.

Authors:  Ji Soo Lee; Daniel Rosoff; Audrey Luo; Martha Longley; Monte Phillips; Katrin Charlet; Christine Muench; Jeesun Jung; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2019-05-03       Impact factor: 3.455

3.  PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.

Authors:  Chun-Yan Wu; Zhi-Han Tang; Lu Jiang; Xue-Fei Li; Zhi-Sheng Jiang; Lu-Shan Liu
Journal:  Mol Cell Biochem       Date:  2011-08-17       Impact factor: 3.396

Review 4.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

5.  PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.

Authors:  Kai Kysenius; Pranuthi Muggalla; Kert Mätlik; Urmas Arumäe; Henri J Huttunen
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

6.  Molecular population genetics of PCSK9: a signature of recent positive selection.

Authors:  Keyue Ding; Iftikhar J Kullo
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

7.  The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).

Authors:  Qi Wu; Zhi-Han Tang; Juan Peng; Ling Liao; Li-Hong Pan; Chun-Yan Wu; Zhi-Sheng Jiang; Gui-Xue Wang; Lu-Shan Liu
Journal:  Biomed Rep       Date:  2013-12-30

Review 8.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

9.  Neuroimmune mechanisms of cognitive impairment in a mouse model of Gulf War illness.

Authors:  Joshua D Bryant; Maheedhar Kodali; Bing Shuai; Saeed S Menissy; Paige J Graves; Thien Trong Phan; Robert Dantzer; Ashok K Shetty; Laura Ciaccia West; A Phillip West
Journal:  Brain Behav Immun       Date:  2021-07-29       Impact factor: 19.227

10.  Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species.

Authors:  Keyue Ding; Samantha J McDonough; Iftikhar J Kullo
Journal:  PLoS One       Date:  2007-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.